Abbisko Cayman Limited (2256.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Yao-Chang Xu
Listed since: Oct 13, 2021
Employees: 276

Market position

Day range

Current HK$9.92

HK$9.76HK$10.37

52-week range

Current HK$9.92

HK$8.34HK$19.78

Open: HK$10.37
Previous close: HK$10.32
Volume: 506K; 0.28× average
Average volume: 1.83M; Average daily volume
Market cap: 7.12B HKD
Beta: 1.2; Market reference 1
50-day average: HK$10.3203; -3.88% below average
200-day average: HK$12.1745; -18.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 6.85B CNY
P/E (TTM): 106.29×
P/B (TTM): 2.76×
P/S (TTM): 9.97×
EV / EBITDA: 140.09×
Earnings yield: 0.74%
Free cash flow yield: 1.01%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 100.00%
Operating margin: 4.56%
Net margin: 9.03%
Return on equity: 2.80%
Return on assets: 2.29%
Return on invested capital: 0.58%

Financial health

Debt / equity: 0.16×
Current ratio: 4.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

596.28M CNY+18.31%

Operating income

27.18M CNY+48.78M CNY

Net income

53.82M CNY+90.15%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	596.28M CNY	503.99M CNY	19.06M CNY	—	22.68M CNY
Gross profit	596.28M CNY	503.99M CNY	19.06M CNY	—	22.68M CNY
Research and development	495.28M CNY	451.38M CNY	433.74M CNY	378.75M CNY	226.13M CNY
Selling, general, and administrative	73.81M CNY	74.21M CNY	35.61M CNY	29.82M CNY	54.84M CNY
Operating expenses	569.09M CNY	525.59M CNY	530.14M CNY	497.19M CNY	336.82M CNY
Interest income	90.51M CNY	89.1M CNY	65.49M CNY	35.02M CNY	16.94M CNY
Interest expense	3.25M CNY	1.61M CNY	2.17M CNY	2.69M CNY	959K CNY
Depreciation and amortization	21.74M CNY	6.32M CNY	18.42M CNY	4.57M CNY	11.89M CNY
Operating income	27.18M CNY	−21.59M CNY	−511.08M CNY	−497.19M CNY	−328.22M CNY
Net income	53.82M CNY	28.3M CNY	−431.58M CNY	−498.29M CNY	−1.81B CNY